Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in severe uncontrolled asthma with elevated eosinophils
NCT03771040Phase 3Completed
- Sponsor
- AB Science
- Start
- Dec 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Masitinib with Placebo (2 arms). Primary endpoint: Severe asthma exacerbation rate. Started Dec 2016; status: completed.
02
Drugs
masitinib
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03771040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03771040.